Design of Dual EP2/EP4 Antagonists through Scaffold Merging of Selective Inhibitors

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Prostaglandin E2 (PGE2) is implicated in cancer progression, including tumorigenesis, metastasis, and immune suppression.
• PGE2 exerts its effects by signaling through EP2 and EP4 receptors.

Purpose of the Study:

• To disclose the structure of novel dual EP2/EP4 antagonists.
• To develop compounds that can counteract PGE2's pro-tumorigenic effects for cancer therapy.

Main Methods:

• Merging scaffolds of selective EP2 and EP4 inhibitors to create dual antagonists.
• In vitro and in vivo profiling of newly identified compounds.

Main Results:

• A new chemical series of compounds effectively blocking both EP2 and EP4 receptors with comparable potency was generated.
• The identified compounds demonstrated promising lead structures in preclinical evaluations.

Conclusions:

• Dual inhibition of EP2 and EP4 receptors presents a viable strategy for cancer treatment.
• The novel dual EP2/EP4 antagonists are promising candidates for further development in oncology.